Phase 4 N=29 Fish Oils and Adipose Inflammation Reduction
Obesity
Primary: Change in Plasma Fractalkine Levels — 0.42; 0.46; 0.48; 0.45 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Occupational Therapy's Role in Promoting Community Wellness Utilizing Sit-Stand Workstations
Musculoskeletal Pain · Musculoskeletal Strain · Sedentary Lifestyle
Primary: Reported Musculoskeletal Discomfort Per Group at 3 Months — 1.43; 1.33; 1.47; 0.46 units on a scale — p=0.9327
Phase 2 N=13 Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
AV Fistula
Primary: Time to AV Fistula Functional Maturation — 169; 145 Days to functional maturation
Phase 2 N=1,063 Prehospital Tranexamic Acid Use for Traumatic Brain Injury
Traumatic Brain Injury
Primary: Dichotomized Glasgow Outcome Scale Extended (GOS-E) at 6 Months — 107; 108; 110; 218 Participants — p=.1809
N/A N=259 The Weigh Forward, Financial Incentives for Maintenance of Weight Loss
Obesity
Primary: Change in Weight, Baseline and 6 Months — -1.9; -1.1 Kilograms
Phase 2 N=354 A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
Herpes Zoster
Primary: Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) — 1.57 Ratio — p=<0.0001
Phase 1 N=27 Drug-Drug Interaction Study: ASP2151 and Midazolam
Healthy
Primary: Peak Plasma Concentration (Cmax) of Midazolam — 34.5; 23.4; 38.8; 36.8 ng/mL
N/A N=407 Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Cirrhosis of Liver
Primary: Detection Rate of Patients With HCC — 27.9; 86.0 percentage of HCC detected on each exam — p=<0.01
Phase 4 N=179 Comparison of PIEB vs CEI for Labor Analgesia
Labor Pain
Primary: Volume of Local Anesthetic Received Through Patient Controlled Epidural Analgesia (PCEA) Per Hour — 4.03; 4.52 milliliters per hour — p=0.17
Phase 1 N=37 A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
Schizophrenia
Primary: Lurasidone Cmax — 32.9; 50.9; 113 ng/ml
N/A N=62 Feasibility, Effectiveness and Efficacy of the PowerSleep Device
Sleep · Sleep Disorders Not Due to A Substance or Known Physiological Condition
Primary: Amount of Slow Wave Activity Detected by the Powersleep Device With and Without Stimulation — 1367.9; 1291.3 microvolts^2 — p=0.061
Phase 3 N=986 Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001
N/A N=3,219 A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Percentage of Patients With Incidence of Adverse Events Who Had Taken at Least One Dose of Trajenta — 7.69 Percentage of patients
Phase 3 N=116 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)
Aspergillosis
Primary: Number of Participants With an Adverse Event — 15; 6; 57; 27 Participants
N/A N=402 Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)
Paroxysmal Atrial Fibrillation (PAF)
Primary: Effectiveness: Percentage of Participants Free of Chronic Treatment Failure (CTF) Through 36 Months — 66.9 Percentage of participants — p=<0.001